Arcadia Biosciences (RKDA) Stock Forecast, Price Target & Predictions

OverviewRevenue Ownership Financials Chart Transcripts

RKDA Stock Forecast

Arcadia Biosciences stock forecast is as follows: an average price target of $6.00 (represents a -3.54% downside from RKDA’s last price of $6.22) and a rating consensus of 'Buy', based on 1 wall street analysts offering a 1-year stock forecast.

RKDA Price Target

The average price target for Arcadia Biosciences (RKDA) is $6.00 based on 1-year price targets from 1 Wall Street analysts in the past 3 months, with a price target range of $6.00 to $6.00. This represents a potential -3.54% downside from RKDA's last price of $6.22.

RKDA Analyst Ratings

Buy

According to 1 Wall Street analysts, Arcadia Biosciences's rating consensus is 'Buy'. The analyst rating breakdown for RKDA stock is 0 'Strong Buy' (0.00%), 1 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Arcadia Biosciences Price Target by Analyst

Date	Analyst	Company	Price Target	Price when Published	Price Target/Price when Published	Price Target/Last Closing Price
May 23, 2024	Raghuram Selvaraju	H.C. Wainwright	$6.00	$2.78	115.83%	-3.54%

The latest Arcadia Biosciences stock forecast, released on May 23, 2024 by Raghuram Selvaraju from H.C. Wainwright, set a price target of $6.00, which represents a 115.83% increase from the stock price at the time of the forecast ($2.78), and a -3.54% decrease from RKDA last price ($6.22).

Arcadia Biosciences Price Target by Period

	1M	3M	12M
# Anlaysts	-	-	1
Avg Price Target	-	-	$6.00
Last Closing Price	$6.22	$6.22	$6.22
Upside/Downside	-100.00%	-100.00%	-3.54%

In the current month, the average price target of Arcadia Biosciences stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Arcadia Biosciences's last price of $6.22. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades

Date	Company	Previous Rating	New Rating	Rating Change
May 23, 2024	H.C. Wainwright	Buy	Buy	Hold

Arcadia Biosciences's last stock rating was published by H.C. Wainwright on May 23, 2024. The company gave RKDA a "Buy" rating, the same as its previous rate.

Arcadia Biosciences Financial Forecast

Arcadia Biosciences Revenue Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Jun 18	Mar 17
Revenue	-	-	-	-	-	-	-	-	-	$1.60M	$1.39M	$1.51M	$1.00M	$1.88M	$3.86M	$3.22M	$2.17M	$2.38M	$1.41M	$828.00K	$7.13M	$314.00K	$281.00K	$309.00K	$416.00K	$392.00K	$203.00K	$158.00K	$436.00K	$1.02M
Avg Forecast	$1.40M	$2.20M	$1.60M	$1.30M	$1.15M	$1.40M	$950.00K	$1.20M	$1.75M	$1.55M	$1.60M	$1.40M	$2.00M	$2.67M	$2.30M	$1.90M	$3.33M	$2.51M	$1.69M	$734.33K	$1.26M	$1.14M	$1.86M	$800.00K	$590.00K	$283.33K	$220.00K	$325.00K	$280.99K	$714.00K
High Forecast	$1.43M	$2.25M	$1.64M	$1.33M	$1.18M	$1.43M	$973.46K	$1.23M	$1.79M	$1.55M	$1.64M	$1.43M	$2.05M	$2.67M	$2.30M	$1.90M	$3.33M	$2.51M	$1.69M	$734.33K	$1.26M	$1.14M	$1.86M	$800.00K	$590.00K	$283.33K	$220.00K	$325.00K	$337.19K	$856.80K
Low Forecast	$1.37M	$2.15M	$1.56M	$1.27M	$1.12M	$1.37M	$926.54K	$1.17M	$1.71M	$1.55M	$1.56M	$1.37M	$1.95M	$2.67M	$2.30M	$1.90M	$3.33M	$2.51M	$1.69M	$734.33K	$1.26M	$1.14M	$1.86M	$800.00K	$590.00K	$283.33K	$220.00K	$325.00K	$224.79K	$571.20K
# Analysts	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	7	5	5	9	6	4	4	7	4	11	12
Surprise %	-	-	-	-	-	-	-	-	-	1.03%	0.87%	1.08%	0.50%	0.70%	1.68%	1.70%	0.65%	0.95%	0.83%	1.13%	5.68%	0.28%	0.15%	0.39%	0.71%	1.38%	0.92%	0.49%	1.55%	1.43%

Arcadia Biosciences's average Quarter revenue forecast for Dec 23 based on 1 analysts is $1.75M, with a low forecast of $1.71M, and a high forecast of $1.79M. RKDA's average Quarter revenue forecast represents a 9.58% increase compared to the company's last Quarter revenue of $1.60M (Sep 23).

Arcadia Biosciences EBITDA Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Jun 18	Mar 17
# Analysts	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	7	5	5	9	6	4	4	7	4	11	12
EBITDA	-	-	-	-	-	-	-	-	-	$-3.24M	$-8.15M	$-4.09M	$-5.95M	$-6.32M	$-5.28M	$-4.81M	$-8.08M	$-2.85M	$-4.98M	$2.32M	$9.04M	$-6.15M	$-9.59M	$2.62M	$-6.19M	$-14.13M	$4.28M	$-12.56M	$-6.61M	$-3.79M
Avg Forecast	$-1.31M	$-2.06M	$-1.50M	$-1.22M	$-1.08M	$-1.31M	$-888.68K	$-1.12M	$-1.64M	$-1.45M	$-1.50M	$-1.31M	$-1.87M	$-2.67M	$-2.30M	$-5.50M	$-3.33M	$-2.51M	$-1.69M	$-734.33K	$-1.26M	$-1.14M	$-1.86M	$-800.00K	$-590.00K	$-283.33K	$-220.00K	$-15.82M	$-3.16M	$-2.38M
High Forecast	$-1.28M	$-2.01M	$-1.46M	$-1.19M	$-1.05M	$-1.28M	$-866.73K	$-1.09M	$-1.60M	$-1.45M	$-1.46M	$-1.28M	$-1.82M	$-2.67M	$-2.30M	$-4.40M	$-3.33M	$-2.51M	$-1.69M	$-734.33K	$-1.26M	$-1.14M	$-1.86M	$-800.00K	$-590.00K	$-283.33K	$-220.00K	$-12.65M	$-2.53M	$-1.90M
Low Forecast	$-1.34M	$-2.11M	$-1.53M	$-1.25M	$-1.10M	$-1.34M	$-910.62K	$-1.15M	$-1.68M	$-1.45M	$-1.53M	$-1.34M	$-1.92M	$-2.67M	$-2.30M	$-6.59M	$-3.33M	$-2.51M	$-1.69M	$-734.33K	$-1.26M	$-1.14M	$-1.86M	$-800.00K	$-590.00K	$-283.33K	$-220.00K	$-18.98M	$-3.79M	$-2.86M
Surprise %	-	-	-	-	-	-	-	-	-	2.24%	5.45%	3.12%	3.18%	2.37%	2.29%	0.87%	2.43%	1.14%	2.95%	-3.16%	-7.20%	5.38%	5.16%	-3.27%	10.49%	49.87%	-19.45%	0.79%	2.09%	1.59%

1 analysts predict RKDA's average Quarter EBITDA for Jun 21 to be $-1.69M, with a high of $-1.69M and a low of $-1.69M. This is -172.71% lower than Arcadia Biosciences's previous annual EBITDA (Mar 21) of $2.32M.

Arcadia Biosciences Net Income Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Jun 18	Mar 17
# Analysts	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	7	5	5	9	6	4	4	7	4	11	12
Net Income	-	-	-	-	-	-	-	-	-	$-2.57M	$823.00K	$-3.85M	$-4.33M	$-2.88M	$-3.78M	$-4.47M	$-9.55M	$-2.84M	$-5.26M	$2.06M	$8.90M	$-6.39M	$-9.69M	$2.52M	$-6.24M	$-14.19M	$4.24M	$-12.61M	$-6.67M	$-4.22M
Avg Forecast	$-872.80K	$-627.33K	$-1.04M	$-1.34M	$-1.21M	$-1.10M	$2.11M	$-3.02M	$-3.53M	$-4.00M	$-6.61M	$-9.00M	$-9.27M	$-11.45M	$-15.81M	$-5.70M	$-16.35M	$-16.08M	$-14.90M	$4.36M	$-22.35M	$-29.62M	$-31.98M	$5.74M	$-31.35M	$-41.98M	$-49.33M	$-15.88M	$-3.18M	$-2.65M
High Forecast	$-844.79K	$-607.18K	$-1.00M	$-1.29M	$-1.17M	$-1.07M	$2.18M	$-2.92M	$-3.41M	$-3.87M	$-6.40M	$-8.71M	$-8.98M	$-11.45M	$-15.81M	$-4.56M	$-16.35M	$-16.08M	$-14.90M	$5.23M	$-22.35M	$-29.62M	$-31.98M	$6.89M	$-31.35M	$-41.98M	$-49.33M	$-12.71M	$-2.55M	$-2.12M
Low Forecast	$-900.81K	$-647.47K	$-1.07M	$-1.38M	$-1.25M	$-1.14M	$2.05M	$-3.12M	$-3.64M	$-4.12M	$-6.82M	$-9.29M	$-9.57M	$-11.45M	$-15.81M	$-6.84M	$-16.35M	$-16.08M	$-14.90M	$3.49M	$-22.35M	$-29.62M	$-31.98M	$4.59M	$-31.35M	$-41.98M	$-49.33M	$-19.06M	$-3.82M	$-3.18M
Surprise %	-	-	-	-	-	-	-	-	-	0.64%	-0.12%	0.43%	0.47%	0.25%	0.24%	0.78%	0.58%	0.18%	0.35%	0.47%	-0.40%	0.22%	0.30%	0.44%	0.20%	0.34%	-0.09%	0.79%	2.09%	1.59%

Arcadia Biosciences's average Quarter net income forecast for Sep 23 is $-4.00M, with a range of $-4.12M to $-3.87M. RKDA's average Quarter net income forecast represents a -585.52% decrease compared to the company's last Quarter net income of $823.00K (Jun 23).

Arcadia Biosciences SG&A Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Jun 18	Mar 17
# Analysts	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	7	5	5	9	6	4	4	7	4	11	12
SG&A	-	-	-	-	-	-	-	-	-	$3.44M	$3.81M	$4.39M	$4.21M	$4.83M	$4.65M	$4.35M	$6.19M	$6.31M	$6.37M	$4.07M	$4.78M	$4.29M	$3.67M	$3.72M	$3.13M	$4.48M	$3.15M	$2.81M	$2.95M	$3.05M
Avg Forecast	$6.04M	$9.49M	$6.90M	$5.61M	$4.96M	$6.04M	$4.10M	$5.18M	$7.55M	$6.67M	$6.90M	$6.04M	$8.63M	$11.51M	$9.92M	$8.19M	$14.38M	$10.82M	$7.29M	$3.17M	$5.42M	$4.93M	$8.01M	$3.45M	$2.55M	$1.22M	$949.22K	$1.40M	$1.21M	$3.08M
High Forecast	$6.19M	$9.73M	$7.07M	$5.75M	$5.08M	$6.19M	$4.20M	$5.31M	$7.74M	$6.67M	$7.07M	$6.19M	$8.84M	$11.51M	$9.92M	$8.19M	$14.38M	$10.82M	$7.29M	$3.17M	$5.42M	$4.93M	$8.01M	$3.45M	$2.55M	$1.22M	$949.22K	$1.40M	$1.45M	$3.70M
Low Forecast	$5.89M	$9.26M	$6.73M	$5.47M	$4.84M	$5.89M	$4.00M	$5.05M	$7.36M	$6.67M	$6.73M	$5.89M	$8.42M	$11.51M	$9.92M	$8.19M	$14.38M	$10.82M	$7.29M	$3.17M	$5.42M	$4.93M	$8.01M	$3.45M	$2.55M	$1.22M	$949.22K	$1.40M	$969.89K	$2.46M
Surprise %	-	-	-	-	-	-	-	-	-	0.52%	0.55%	0.73%	0.49%	0.42%	0.47%	0.53%	0.43%	0.58%	0.87%	1.28%	0.88%	0.87%	0.46%	1.08%	1.23%	3.66%	3.31%	2.01%	2.43%	0.99%

Arcadia Biosciences's average Quarter SG&A projection for Dec 23 is $7.55M, based on 1 Wall Street analysts, with a range of $7.36M to $7.74M. The forecast indicates a 119.30% rise compared to RKDA last annual SG&A of $3.44M (Sep 23).

Arcadia Biosciences EPS Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Jun 18	Mar 17
# Analysts	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	7	5	5	9	6	4	4	7	4	11	12
EPS	-	-	-	-	-	-	-	-	-	$-1.89	$0.61	$-4.49	$-7.22	$-4.69	$-6.81	$-8.07	$-0.43	$-0.10	$-0.24	$0.11	$0.83	$-0.60	$-1.04	$0.29	$-0.72	$-2.04	$0.84	$-2.64	$-2.02	$-2.00
Avg Forecast	$-0.64	$-0.46	$-0.76	$-0.98	$-0.89	$-0.81	$1.55	$-2.21	$-2.58	$-2.93	$-4.84	$-6.60	$-6.80	$-8.40	$-11.60	$-13.60	$-12.00	$-11.80	$-10.93	$-13.73	$-16.40	$-21.73	$-23.47	$-21.80	$-23.00	$-30.80	$-36.20	$-32.40	$-0.62	$-0.88
High Forecast	$-0.62	$-0.45	$-0.74	$-0.95	$-0.86	$-0.78	$1.60	$-2.14	$-2.50	$-2.84	$-4.69	$-6.39	$-6.58	$-8.40	$-11.60	$-13.60	$-12.00	$-11.80	$-10.93	$-13.73	$-16.40	$-21.73	$-23.47	$-21.80	$-23.00	$-30.80	$-36.20	$-32.40	$-0.49	$-0.70
Low Forecast	$-0.66	$-0.47	$-0.78	$-1.01	$-0.92	$-0.84	$1.50	$-2.29	$-2.67	$-3.02	$-5.00	$-6.81	$-7.02	$-8.40	$-11.60	$-13.60	$-12.00	$-11.80	$-10.93	$-13.73	$-16.40	$-21.73	$-23.47	$-21.80	$-23.00	$-30.80	$-36.20	$-32.40	$-0.74	$-1.06
Surprise %	-	-	-	-	-	-	-	-	-	0.65%	-0.13%	0.68%	1.06%	0.56%	0.59%	0.59%	0.04%	0.01%	0.02%	-0.01%	-0.05%	0.03%	0.04%	-0.01%	0.03%	0.07%	-0.02%	0.08%	3.26%	2.27%

According to 1 Wall Street analysts, Arcadia Biosciences's projected average Quarter EPS for Sep 23 is $-2.93, with a low estimate of $-3.02 and a high estimate of $-2.84. This represents a -580.33% decrease compared to RKDA previous annual EPS of $0.61 (Jun 23).

RKDA Forecast FAQ

Is Arcadia Biosciences a good buy?

Yes, according to 1 Wall Street analysts, Arcadia Biosciences (RKDA) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 1 'Buy' recommendations, accounting for 100.00% of RKDA's total ratings.

What is RKDA's price target?

Arcadia Biosciences (RKDA) average price target is $6 with a range of $6 to $6, implying a -3.54% from its last price of $6.22. The data is based on 1 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Arcadia Biosciences stock go up soon?

According to Wall Street analysts' prediction for RKDA stock, the company can go down by -3.54% (from the last price of $6.22 to the average price target of $6), down by -3.54% based on the highest stock price target, and down by -3.54% based on the lowest stock price target.

Can Arcadia Biosciences stock reach $9?

RKDA's average twelve months analyst stock price target of $6 does not support the claim that Arcadia Biosciences can reach $9 in the near future.

What are Arcadia Biosciences's analysts' financial forecasts?

Arcadia Biosciences's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $4.7M (high $4.82M, low $4.58M), average EBITDA is $-4.397M (high $-4.288M, low $-4.505M), average net income is $-3.225M (high $-2.986M, low $-3.465M), average SG&A $20.28M (high $20.78M, low $19.78M), and average EPS is $-2.365 (high $-2.19, low $-2.54). RKDA's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $6.5M (high $6.66M, low $6.34M), average EBITDA is $-6.08M (high $-5.93M, low $-6.231M), average net income is $-3.873M (high $-3.749M, low $-3.997M), average SG&A $28.05M (high $28.74M, low $27.35M), and average EPS is $-2.84 (high $-2.749, low $-2.931).

Did the RKDA's actual financial results beat the analysts' financial forecasts?

Based on Arcadia Biosciences's last annual report (Dec 2023), the company's revenue was $5.33M, which missed the average analysts forecast of $6.3M by -15.34%. Apple's EBITDA was $-13.938M, beating the average prediction of $-5.889M by 136.67%. The company's net income was $-13.981M, missing the average estimation of $-23.129M by -39.55%. Apple's SG&A was $14.51M, missing the average forecast of $27.16M by -46.59%. Lastly, the company's EPS was $-0.0113, missing the average prediction of $-16.96 by -99.93%. In terms of the last quarterly report (Sep 2023), Arcadia Biosciences's revenue was $1.6M, beating the average analysts' forecast of $1.55M by 3.33%. The company's EBITDA was $-3.242M, beating the average prediction of $-1.446M by 124.25%. Arcadia Biosciences's net income was $-2.567M, missing the average estimation of $-3.996M by -35.76%. The company's SG&A was $3.44M, missing the average forecast of $6.67M by -48.37%. Lastly, the company's EPS was $-1.89, missing the average prediction of $-2.93 by -35.49%